Leading PI: Andriy Luzhetskyy (University of Saarland) & Christoph Wittmann (University of Saarland)
This proposal aims to create actinobacterial cell factories with synthetic pathways for relevant therapeutics and integrated sensing and control circuits for signal transduction, communication and streamlined output. Joint efforts of all partners will couple synthetic and control properties into cells of higher functionality. In addition, possibilities to combine cells with different performance into synthetic consortia will be explored. Within the consortium, collaboration with other LSC partners aim to combine the cell factories with polymers into living materials and test them for medical applications.
Related Publications:
Oberhäuser P, Myronovskyi M, Stierhof M, Gromyko O, Luzhetskyy A. Identification and heterologous expression of an NRPS biosynthetic gene cluster responsible for the production of the pyrazinones Ichizinone A, B and C. Microb Cell Fact. 2025 Jun 7;24(1):131. doi: 10.1186/s12934-025-02753-6. PMID: 40481494; PMCID: PMC12144821
Ahmed Y, Rebets Y, Estévez MR, Zapp J, Myronovskyi M, Luzhetskyy A. Engineering of Streptomyces lividans for heterologous expression of secondary metabolite gene clusters. Microb Cell Fact. 2020 Jan 9;19(1):5. doi: 10.1186/s12934-020-1277-8. PMID: 31918711; PMCID: PMC6950998.
Eckert N, Rebets Y, Horbal L, Zapp J, Herrmann J, Busche T, Müller R, Kalinowski J, Luzhetskyy A. Discovery and overproduction of novel highly bioactive pamamycins through transcriptional engineering of the biosynthetic gene cluster. Microb Cell Fact. 2023 Nov 14;22(1):233. doi: 10.1186/s12934-023-02231-x. PMID: 37964282; PMCID: PMC10644645.
